[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 1997

Treating Patients With Melanoma With Interferon

Author Affiliations

Shadyside Medical Center 5200 Centre Ave, Suite 303 Pittsburgh, PA 15232

Arch Dermatol. 1997;133(3):387. doi:10.1001/archderm.1997.03890390131022

We are writing to express our concerns about the advertised indications for treating patients with melanoma with interferon. In 1995 the US Food and Drug Administration approved the use of interferon alfa-2b for patients with high-risk melanomas who are free of disease but at risk for recurrence following surgical treatment. The approval was based on a study1 showing improved survival rates with interferon treatment. This approval has been followed by an aggressive advertisement campaign by the drug's manufacturer. With this new hope for successful treatment, it is important that physicians understand the limitations of adjuvant interferon therapy—especially given the drug's cost, toxicity, and response rates.

The benefits of adjuvant interferon therapy are debatable and varied among published studies.1-3 The previously mentioned prospective trial1 was the first randomized adjuvant therapy study to show a survival benefit and therefore resulted in a rapid approval of interferon use by the